SML0802
ZLN005
≥95% (HPLC)
别名:
2-(4-tert-Butylphenyl)-1H-benzimidazole, 2-[4-(1,1-Dimethylethyl)phenyl]-1H-benzimidazole
SMILES string
[nH]1c2c(nc1c3ccc(cc3)C(C)(C)C)cccc2
InChI
1S/C17H18N2/c1-17(2,3)13-10-8-12(9-11-13)16-18-14-6-4-5-7-15(14)19-16/h4-11H,1-3H3,(H,18,19)
InChI key
LQUNNCQSFFKSSK-UHFFFAOYSA-N
assay
≥95% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 10 mg/mL, clear
storage temp.
−20°C
Quality Level
Biochem/physiol Actions
ZLN005 is a transcriptional regulator of peroxisome proliferator-activated receptor-γ coactivator-1α (PGC-1α). ZLN005 increased PGC-1 and downstream gene transcription in skeletal muscle, while reducing hepatic PGC-1α and gluconeogenesis genes. ZLN005 increased fat oxidation and improved the glucose tolerance, pyruvate tolerance, insulin sensitivity, hyperglycemia and dyslipidemia of diabetic db/db mice.
ZLN005 is a transcriptional regulator of peroxisome proliferator-activated receptor-γ coactivator-1α.
存储类别
11 - Combustible Solids
wgk
WGK 3
Tianyu Hang et al.
International journal of molecular sciences, 24(10) (2023-05-27)
Type-2 diabetes (T2DM) and arterial hypertension (HTN) are major risk factors for heart failure. Importantly, these pathologies could induce synergetic alterations in the heart, and the discovery of key common molecular signaling may suggest new targets for therapy. Intraoperative cardiac
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持